A detailed examination of each major stakeholder in this modern industrial revolution in our inaugural column in Orthopedic Design & Technology Magazine.

Capitalizing on these opportunities will allow medtech organizations to continue to grow well into the future. Read more in our February column in MPO.

Improve your value proposition for today and tomorrow.

The FDA’s recent draft guidance on medical devices with software will require companies’ complete attention.

Scalability should be on top of the list of strategic topics regardless of a company’s size or stage.

The FTC and the EU’s scrutiny of healthcare/life sciences M&A plays a vital role in shaping the industry’s core markets.

In a world where Digital Health and AI are buzzwords: what happened to medical device manufacturing? Is it still a positive business to be in? What’s the long-term outlook? What’s the geopolitical climate for this type of manufacturing? Should I continue to invest and grow?

Major MedTech corporations often engage in acquisitions to drive their growth and market dominance.

Is Europe’s regulatory burden a loss for the EU and a gain for the U.S.?

Blood-based molecular cancer test delivers accuracy and specificity levels unsurpassed by other diagnostic methods.

Dave and Florence review the M&A activity for the top 12 highest-grossing medtech companies since 2022 in this months MPO column.

With potential acquirers contacting us every week seeking a company in one of the categories, it’s clear the medical M&A market is still highly active in 2023! For further validation, our frequent flyer miles this year are higher than ever.

Ortoma to present groundbreaking 2D-3D technology for knee and hip joints at the annual ISTA congress in New York 2023.